Carlyle Group buys diagnostics business from J&J
- J&J is selling its Ortho-Clinical Diagnostics (OCD) to the Carlyle Group.
- OCD specializes in in vitro diagnostics and provides screening, diagnostic and monitoring services.
- OCD generated $1.9 billion in 2013.
The Carlyle Group is strategically positioning itself as a global player in the pharmaceutical industry. So far it has invested $6.3 billion in equity in the industry, including this $4 billion deal. Other deals include Chesapeake, a pharma packaging specialist company in the UK; Pharmaceutical Product Development; Group Qualicorp; Healthscope; HCK; ManorCare and MultiPlan.
- pharmafile.com J&J completes $4 billion OCD sale